H%CIWb S} } mo36Vo+ a|-B,=w3mB- 9V-%P 0 Xh7A1 Hfv}{0p3~ T7EZ-hZ8mEm- [F7] (HhP#(O(H /+ vgn(83n( GL}l r)70`@)U=r)_r09rCr: fZAZ\ #C{rN/# %/i8GJ6/l=6 3}Zp}b~[ b%FFO. @2T @!zR,#z k) o&` +PL aFA~z 9N9]H|X| FD lLL0 bIE9r 2oX B!aGaU6al Rb 8XKc iS83MT993.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/vou)^tC& population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.